207 related articles for article (PubMed ID: 15742461)
1. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
van den Brande J; Hommes DW; Peppelenbosch MP
J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
[TBL] [Abstract][Full Text] [Related]
2. Diverse effects of infliximab and etanercept on T lymphocytes.
Sieper J; Van Den Brande J
Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
[TBL] [Abstract][Full Text] [Related]
3. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
4. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
[TBL] [Abstract][Full Text] [Related]
5. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.
Rahimi R; Nikfar S; Abdollahi M
Biomed Pharmacother; 2007 Jan; 61(1):75-80. PubMed ID: 17184965
[TBL] [Abstract][Full Text] [Related]
6. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
Rigby WF
Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
[TBL] [Abstract][Full Text] [Related]
7. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitors of TNFalpha].
Brousse C
Rev Med Interne; 2003 Feb; 24(2):123-6. PubMed ID: 12650894
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
[TBL] [Abstract][Full Text] [Related]
10. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target.
Boettger MK; Hensellek S; Richter F; Gajda M; Stöckigt R; von Banchet GS; Bräuer R; Schaible HG
Arthritis Rheum; 2008 Aug; 58(8):2368-78. PubMed ID: 18668541
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of latent granulomatous infections by infliximab.
Wallis RS; Broder M; Wong J; Lee A; Hoq L
Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899
[TBL] [Abstract][Full Text] [Related]
15. Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.
Sheehy C; Murphy E; Barry M
Rheumatology (Oxford); 2006 Oct; 45(10):1314-5. PubMed ID: 16837474
[No Abstract] [Full Text] [Related]
16. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
17. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
[TBL] [Abstract][Full Text] [Related]
18. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
19. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.
Ganesan S; Travis SP; Ahmad T; Jazrawi R
Curr Opin Investig Drugs; 2002 Sep; 3(9):1301-6. PubMed ID: 12498004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
